Revvity Pre-Announces Strong Q4 and Full Year 2025 Results, Exceeding EPS Guidance
RVTY sits 35% above its 52-week low of $81.36 on elevated volume (1.9× avg).
Summary
Revvity, Inc. announced preliminary financial results for the fourth quarter and full year 2025, with adjusted earnings per share expected to exceed the high end of previous guidance, signaling strong performance.
Key Events · Earnings and Guidance · RVTY
-
Preliminary Q4 and Full Year 2025 Revenue
Revvity expects Q4 2025 revenue of approximately $772 million, with reported growth of 6% and organic growth of 4%. Full year 2025 revenue is projected at approximately $2,855 million, with reported growth of 4% and organic growth of 3%.
-
Upgraded Full Year Adjusted EPS Guidance
The company anticipates its full year 2025 adjusted earnings per share to surpass the upper end of its previously provided guidance range of $4.90-$5.00.
-
J.P. Morgan Healthcare Conference Presentation
President and CEO, Dr. Prahlad Singh, is scheduled to present at the 44th Annual J.P. Morgan Healthcare Conference, with presentation materials furnished as an exhibit.
Analysis · RVTY · Industrial Applications And Services
Revvity's preliminary financial update indicates stronger-than-expected performance, particularly with the adjusted EPS forecast to exceed prior guidance. This positive pre-announcement suggests healthy operational execution and could lead to a favorable market reaction. Investors will likely focus on the detailed results and any forward-looking commentary during the upcoming earnings call and the J.P. Morgan Healthcare Conference presentation for further insights into the company's trajectory and strategic initiatives.
At the time of this filing, RVTY was trading at $110.14 on NYSE in the Industrial Applications And Services sector, with a market capitalization of approximately $12.5B. The 52-week trading range was $81.36 to $128.29. This filing was assessed with positive market sentiment and an importance score of 7 out of 10.